Pierre Fabre acquisition
This article was originally published in The Rose Sheet
French Pharmaceutical company forms Pierre Fabre Dermo Cosmetique USA subsidiary to acquire Genesis Pharmaceutical and C&M Pharmacal, marketers of Glytone and Wellskin skin care lines through dermatologists, firm announces Oct. 2. Acquisition is first step in Pierre Fabre's dermo cosmetic strategy in the U.S., company adds. Pierre Fabre will supplement Genesis' products with its own beginning with U.S. launch of Eau Thermale Avene, the company's main dermo cosmetic brand. New subsidiary will be headed by President Olivier Fontaine. Genesis President and CEO Leonard Mazur will retain his current position...
You may also be interested in...
Per- and polyfluoroalkyl substances (PFAS) are under increasing scrutiny in the US and Europe. Stakeholders have until 31 July to submit information to the authorities of five European countries as they prepare a joint proposal for a broad PFAS restriction under the bloc’s REACH regulation.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.